Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.

J Immunol. 1996 Dec 1;157(11):4811-21. Unique Identifier : AIDSLINE MED/97098706
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE; Transplantation Therapy Section, Medical Oncology Branch,; National Cancer Institute, National Institutes of Health,; Bethesda, MD 20892, USA.

Abstract: Allogeneic CD8+ T cells mediate both a graft-vs-leukemia (GVL) effect and graft-vs-host disease (GVHD). To evaluate whether CD8 cells of defined cytokine phenotype differentially mediate these processes, alloreactive donor CD8+ T cells preferentially secreting type I or type II cytokines were generated by alloantigenic priming in vitro in the presence of IL-12 or IL-4, respectively. Both cytokine-secreting subsets lysed allogeneic tumor targets in vitro ("Tc1" and "Tc2" subsets). A transplantation model was established (B6 into B6C3F1, 1050 cGy host irradiation) using the 32Dp210 myeloid line (bcr/abl transfected, H-2k; 1 x 10(4) tumor cells/recipient). Compared with leukemia controls (death at 12.9 days post-bone marrow transplantation), both Tc1 and Tc2 recipients were conferred a survival advantage. At cell doses of 2 to 2.5 x 10(7), the Tc1-mediated GVL effect (mean survival of 34.2 days) was more potent than the Tc2-mediated GVL effect (mean survival of 20.5 days; Tc1 > Tc2, p = 0.009). On day 15, histologic examination showed that Tc1 recipients had undetectable tumor burdens, whereas Tc2 recipients had extensive leukemic infiltrates. However, Tc2 recipients had essentially no histologic evidence of GVHD, whereas Tc1 recipients had mild to moderate GVHD (average GVHD scores of 1/40 and 9.3/40, respectively). In contrast, recipients of uncultured CD8+ donor T cells developed severe GVHD (average GVHD score of 26.7/40). Because in vitro-generated, alloreactive Tc1 and Tc2 populations mediated GVL with reduced GVHD, we conclude that both subsets may improve the therapeutic outcome of allogeneic T cell transfers in patients with leukemia.

Keywords: Acetylcysteine/PHARMACOLOGY Animal Bone Marrow Transplantation/IMMUNOLOGY/PATHOLOGY Cytokines/SECRETION Cytotoxicity, Immunologic CD8-Positive T-Lymphocytes/*CLASSIFICATION/DRUG EFFECTS/ *IMMUNOLOGY Graft vs Host Disease/ETIOLOGY/*IMMUNOLOGY/PATHOLOGY Graft vs Host Reaction/*IMMUNOLOGY Graft Survival/IMMUNOLOGY Human In Vitro Intestines/IMMUNOLOGY/PATHOLOGY Leukemia, Experimental/*IMMUNOLOGY/PATHOLOGY/*THERAPY Ligands Liver/IMMUNOLOGY/PATHOLOGY Membrane Glycoproteins/IMMUNOLOGY Mice Mice, Inbred C3H Mice, Inbred C57BL Neoplasm Transplantation Support, Non-U.S. Gov't T-Lymphocyte Subsets/*IMMUNOLOGY Transplantation, Homologous JOURNAL ARTICLE
970228
M9721853

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .